NMD Pharma shared new data from its Phase 2a SYNAPSE-CMT clinical trial evaluating the investigational drug ignaseclant during a late-breaking presentation at the 2026 MDA Clinical & Scientific Conference.
Our Trip to Europe
By Julie Richardson My mom is 83 years old. She has never owned a passport....
CMTA Board of Directors Welcomes New Chair and Two New Members
The Charcot-Marie-Tooth Association named Wendy Arnone as chair of its Board of Directors and appointed...
We Go Where the Science Goes: 2025 CMTA Research Highlights
By Katherine Forsey, PhD Each year, I’m reminded that progress in CMT research is built...
What Your Inner Ear Could Tell Us About CMT Treatment
Progress in treating CMT depends on finding therapies that work and measuring how well they...
Why participate in a clinical trial?
By Sue Bruhn, PhD Medical progress doesn’t happen by accident. Every treatment we rely on...
The Last Mile: Delivering CMT Therapies to the Nerves in Need
Developing a treatment is only half the challenge. The other half is getting it to...
Halfway Up the Stairs: How One Family Turned Heartbreak Into Hope
The idea to fundraise for CMTA didn’t start with a plan. It started with a...
CMTA-STAR Alliance Partner NMD Pharma Shares SYNAPSE-CMT Trial Update
New Phase 2a CMT trial results are in. NMD Pharma shares details.
When Early Testing Shows a Program Is Worth Continuing
Some research ideas reach a point where early testing answers an important question: Is this work worth continuing? For EverTree Bio, that moment came through early work using the CMTA Preclinical Toolbox.
